SLXN earnings analysis
What we found in SLXN's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The provided 10-Q excerpt does not include the quarterly income statement, balance sheet, cash flow statement, segment results, or MD&A, so revenue, margins, EPS, liquidity, and free cash flow cannot be assessed. Controls were reported effective as of June 30, 2026, but the company faces material litigation over the $3.433 million sponsor promissory note and ongoing equity and warrant activity. No quantitative guidance was provided in the available filing text.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Controls remained effective
- Management concluded that disclosure controls and procedures were effective as of June 30, 2026, and reported no material change in internal control over financial reporting during the quarter.
- Warrant exercise transaction completed
- The company completed an induced warrant exercise transaction on May 18, 2026, involving issuance of ordinary shares and new warrants.
- Authorized share capital expanded
- The authorized share capital was increased to $2,146,500, representing 15,900,000 ordinary shares with a $0.135 par value, on July 21, 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Sponsor promissory note litigation
- Moringa Sponsor filed a complaint on June 22, 2026, seeking repayment of the $3.433 million original principal amount of the A&R Sponsor Promissory Note plus damages; the company is preparing its defense.
- Potential warrant dilution
- The May 18, 2026 induced warrant exercise transaction included issuance of new warrants and placement-agent warrants, creating potential future equity dilution.
- Significant equity restructuring
- The company completed a 1-for-10 reverse share split on May 29, 2026, and subsequently increased authorized capital to 15,900,000 ordinary shares, reflecting substantial equity-structure changes.
What they said about what is next.
The provided 10-Q excerpt contains no quantitative revenue or EPS outlook. No explicit guidance was provided.
The filing reads worse than the one before it.
What came before.
- 10-K · May 19, 2026
- Silexion Therapeutics reported a challenging fiscal year ending December 31, 2025, with a significant EPS loss of -1.40 in its recent Q4 results and no reported revenue, signaling difficulties in its revenue generation.…
- 10-Q · May 15, 2026
- Silexion Therapeutics reported a substantial net loss of $2.7 million for Q1 2026, increasing 58.8% year-over-year. Operating expenses doubled primarily due to significant investments in research and development as they…
- 10-K · March 17, 2026
- Silexion is a clinical-stage oncology biotech focused on silencing KRAS with siRNA; its lead candidate SIL204 uses an integrated intratumoral + subcutaneous regimen in combination with standard chemotherapy and is being…
- 10-Q · August 12, 2025
- Silexion reported no revenue for the quarter and posted a larger net loss as operating expenses accelerated. The company materially improved liquidity via equity raises (public offering and warrant exercises) — cash and…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing SLXN makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever